Patents by Inventor J. Monty Watkins

J. Monty Watkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20230192835
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: September 9, 2022
    Publication date: June 22, 2023
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • ANTI-ROR1 ANTIBODIES AND COMPOSITIONS
    Publication number: 20230021388
    Abstract: This invention relates to anti-ROR1 antibodies and methods of using them in treating diseases and conditions related to ROR1 activity, e.g., cancer.
    Type: Application
    Filed: February 5, 2021
    Publication date: January 26, 2023
    Applicant: VelosBio Inc.
    Inventors: Jeffry D. WATKINS, Thanh-Trang VO, J. Monty WATKINS
  • Optimized anti-TL1A antibodies
    Patent number: 11440954
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 13, 2022
    Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • ANTI-ROR1 / ANTI-CD3 BISPECIFIC BINDING MOLECULES
    Publication number: 20220227866
    Abstract: This invention relates to bispecific binding molecules that bind to ROR1 and CD3, and methods of using them to treat diseases and conditions such as cancer.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 21, 2022
    Applicant: VelosBio Inc.
    Inventors: Jeffry D. Watkins, Katti Jessen, Mira Ko, Brian Lannutti, Thanh-Trang Vo, J. Monty Watkins
  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20210070871
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohns Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: April 24, 2019
    Publication date: March 11, 2021
    Inventors: Jeffry D. WATKINS, Cindy T. DICKERSON, J. Monty WATKINS, Patricia MCNEELEY
  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20200255510
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins
  • Optimized anti-TL1A antibodies
    Patent number: 10689439
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: June 23, 2020
    Assignee: Prometheus Biosciences, Inc.
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins
  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20200157203
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: November 25, 2019
    Publication date: May 21, 2020
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins